Jennison Associates’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Jennison Associates’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-317,668	Closed	-$1.91M	–	714
2017 Q4	$1.91M	Sell	317,668 -13,990	-4%	-$84.2K	﹤0.01%	537
2017 Q3	$1.84M	Hold	331,658	–	–	﹤0.01%	557
2017 Q2	$1.54M	Sell	331,658 -8,631	-3%	-$38.5K	﹤0.01%	549
2017 Q1	$1.68M	Buy	+340,289	New	+$3.27M	﹤0.01%	553
2015 Q2	–	Sell	-1,088,495	Closed	-$10.1M	–	781
2015 Q1	$10.1M	Buy	1,088,495 +480,847	+79%	+$4.3M	0.01%	494
2014 Q4	$4.26M	Sell	607,648 -17,352	-3%	-$99.3K	﹤0.01%	517
2014 Q3	$3.41M	Buy	+625,000	New	+$3.59M	﹤0.01%	538

Other funds holding FOMX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Jennison Associates's FOMX Position: Q1 2018 in Review

Jennison Associates sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2018, closing a stake of 317,668 shares — an estimated $1.91M sold.

Jennison Associates first reported a position in FOMX in Q3 2014 and held it in 7 quarters. The position peaked at $10.1M in Q1 2015. 56 funds tracked by Wall St. Rank hold FOMX as of Q1 2018.

Jennison Associates reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2018 after selling out during the quarter.
Jennison Associates sold 317,668 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2018, an estimated $1.91M.
Jennison Associates first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2014 and held it in 7 quarters.
Jennison Associates's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $10.1M in Q1 2015.
56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2018.

Based on Jennison Associates's 13F filing for Q1 2018, filed 20 Apr 2018.